title: Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.
abstract: OBJECTIVE
  We studied the prevalence and related risk factors of impulse control disorders in Chinese Parkinson's disease patients.
  
  
  METHODS
  We screened all non-demented Parkinson's disease patients attending our Parkinson's disease clinic from August 2009 to March 2010. The clinical characteristics of patients with impulse control disorders and those without were compared.
  
  
  RESULTS
  Of the 213 PD subjects screened, 15 (7.0%) with impulse control disorders were identified. Fourteen of these subjects were on both a dopamine agonist and Levodopa, and one was on Levodopa alone. Of the fourteen subjects on both a dopamine agonist and Levodopa, eleven were on bromocriptine and Levodopa; 10.5% of the subjects exposed to bromocriptine had impulse control disorder. Upon multivariate analysis, dose of dopamine agonist used, young age at onset of Parkinson's disease and a history of anxiety or depression were independent predictors for developing impulse control disorders.
  
  
  CONCLUSIONS
  7% of our Chinese PD subjects had impulse control disorders. When young Parkinson's disease patients with a history of anxiety or depression are treated with high dose of DA, they are at risk of developing impulse control disorders.
authors.affiliation: Department of Medicine, Pamela Youde Nethersole Eastern Hospital, 3rd Lok Man Road, Chai Wan, Hong Kong Special Administrative Region, China. auyema@yahoo.com.hk
authors.forename: M
authors.initials: M
authors.lastname: Auyeung
authors.forename: T H
authors.initials: TH
authors.lastname: Tsoi
authors.forename: W K
authors.initials: WK
authors.lastname: Tang
authors.forename: C M
authors.initials: CM
authors.lastname: Cheung
authors.forename: C N
authors.initials: CN
authors.lastname: Lee
authors.forename: R
authors.initials: R
authors.lastname: Li
authors.forename: Eric
authors.initials: E
authors.lastname: Yeung
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D044466:Asian People / Q000208:ethnology* / Q000523:psychology; D001971:Bromocriptine / Q000008:administration & dosage* / Q000009:adverse effects; D002681:China / Q000453:epidemiology / Q000208:ethnology; D003430:Cross-Sectional Studies; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced / Q000208:ethnology* / Q000523:psychology; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004876:Ergot Alkaloids / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000208:ethnology* / Q000523:psychology; D011446:Prospective Studies
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004876:Ergot Alkaloids; D001971:Bromocriptine; D007980:Levodopa